James Rosenbaum, MD
Rheumatology · Portland, ORNPI 1962454280
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $74,095 of the $84,417 with a category attached, or 87.8%. 11 manufacturers reported payments, led by Novartis Pharma AG at 31.4% of the total. Reporting peaked in 2020 at $32,594 and has fallen 99.9% since, to $21 in 2023. Among rheumatology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $1623.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Pharma AG$27K
- AbbVie$22K
- Amgen$10K
- Gilead$9K
- Novartis$7K
- UCB SA$4K
- plus $7K from 5 others
Across 34 payments — averaging $11,857 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$314K
- Amgen$62K
- Bristol Myers Squibb$14K
- Gilead$8K
- UCB, Inc.$6K
- Novartis Pharma AG$559
What the payments were for
- Consulting fees$74,09588%
- Speaking & faculty fees$8,25010%
- Travel & lodging$1,3642%
- Food & beverage$6961%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Pharma AG | 9 | $26,520 |
| AbbVie | 20 | $21,862 |
| Amgen | 7 | $9,725 |
| Gilead | 6 | $8,507 |
| Novartis | 3 | $6,670 |
| UCB SA | 1 | $3,840 |
| Bristol Myers Squibb | 1 | $3,386 |
| Eli Lilly | 2 | $2,914 |
| UCB, Inc. | 1 | $960 |
| Lilly USA, LLC | 1 | $21 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,417 in reported general payments places this provider in the 90th percentile of 79 rheumatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 13 | $219 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Portland
- Atulya DeodharPortland$694K
- Rosario BonafedePortland$148K
- Kelly PortnoffPortland$13K
- Neha Rich-GargPortland$11K
- Cong Qiu ChuPortland$5K
- Rashmi ShahPortland$5K
- Caroline McCulleyPortland$4K
- John GriffinPortland$2K
- Whitney Elg-SalsmanPortland$981
- Anne VettoPortland$337
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.